CRISPR Q2 CASGEVY revenue $76M (+151% YoY); FDA expands approval to children 2+

CRISPR Therapeutics AG

CASGEVY Q2 revenue $76M, up 78% QoQ and 151% YoY; FDA approved for children 2+ with SCD/TDT, adding ~5,500 eligible patients.
Initiated Phase 1 trials for CTX340 (refractory hypertension) and CTX460 (alpha-1 antitrypsin deficiency) using in vivo LNP delivery.
Cash $2.36B at June 30, 2026, up from $1.98B at Dec 31, 2025, boosted by $585M convertible note issuance.
Net loss narrowed to $91.2M from $208.5M in Q2 2025, driven by lower acquired IPR&D and higher CASGEVY revenue.
Phase 1b update for CTX310 (ANGPTL3) expected at ESC Congress Aug 28; Phase 2 for CTX611 (FXI siRNA) ongoing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.